{
  "ticker": "VIR",
  "company_name": "Vir Biotechnology, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04423393",
      "title": "Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Hepatitis B",
      "start_date": "2020-05-26",
      "completion_date": "2022-11-25",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT06491563",
      "title": "Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFN\u03b1 Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "For Treatment of Chronic Hepatitis B Virus Infection",
      "start_date": "2024-08-06",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Brii Biosciences Limited"
    },
    {
      "nct_id": "NCT04913675",
      "title": "Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Covid19",
      "start_date": "2021-06-10",
      "completion_date": "2023-03-24",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT05612581",
      "title": "A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Hepatitis B, Chronic",
      "start_date": "2023-05-10",
      "completion_date": "2025-08-19",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT04891770",
      "title": "Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chronic Hepatitis B",
      "start_date": "2021-08-14",
      "completion_date": "2024-07-19",
      "enrollment": 0,
      "sponsor": "Gilead Sciences"
    },
    {
      "nct_id": "NCT04501978",
      "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Covid19",
      "start_date": "2020-08-04",
      "completion_date": "2023-07-14",
      "enrollment": 0,
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
    },
    {
      "nct_id": "NCT06960395",
      "title": "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR",
      "start_date": "2025-07-22",
      "completion_date": "2029-08",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT07142811",
      "title": "A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Viral Hepatitis",
      "start_date": "2025-08-05",
      "completion_date": "2030-07",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT04634409",
      "title": "A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "COVID-19",
      "start_date": "2020-10-29",
      "completion_date": "2021-10-18",
      "enrollment": 0,
      "sponsor": "Eli Lilly and Company"
    },
    {
      "nct_id": "NCT04749368",
      "title": "Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hepatitis B, Chronic",
      "start_date": "2021-04-12",
      "completion_date": "2023-07-04",
      "enrollment": 0,
      "sponsor": "Brii Biosciences Limited"
    }
  ],
  "summary": {
    "total_trials": 35,
    "by_phase": {
      "PHASE1": 11,
      "PHASE2": 13,
      "PHASE3": 5,
      "PHASE1, PHASE2": 3,
      "": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 17,
      "ACTIVE_NOT_RECRUITING": 7,
      "TERMINATED": 5,
      "RECRUITING": 5,
      "NO_LONGER_AVAILABLE": 1
    },
    "active_trials": 12,
    "completed_trials": 17,
    "conditions": [
      "COVID-19",
      "COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm",
      "Chronic Hepatitis B",
      "Chronic Hepatitis B Virus Infection",
      "Covid19",
      "Covid19, SARS-CoV Infection",
      "For Treatment of Chronic Hepatitis B Virus Infection",
      "HIV I Infection",
      "Hepatic Impairment, Cirrhosis",
      "Hepatitis B, Chronic",
      "Hepatitis D, Chronic",
      "Hormone-refractory Prostate Cancer",
      "Influenza A",
      "Locally Advanced or Metastatic HER2-Expressing Cancers",
      "Renal Impairment",
      "Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR",
      "Viral Hepatitis"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:47.460727",
    "search_query": "Vir Biotechnology, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Vir+Biotechnology,+Inc."
  }
}